Dr. Christopher H. Vandyck, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Medical school
- Northwestern University Feinberg Medical School (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 14
Licensed in Connecticut since 1986, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Northwestern University Feinberg Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
CT license 027403 (first issued 1986; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 14
- Services billed
- 26
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Escitalopram Oxalate Other prescribers in New Haven, CT | 50 |
| Donepezil Hcl Other prescribers in New Haven, CT | 48 |
| Olanzapine Other prescribers in New Haven, CT | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $10,318 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $5,537 |
|---|---|
| Eisai Inc. | $3,326 |
| UCB SA | $1,375 |
| F. Hoffmann-la Roche AG | $80.00 |
| Consulting Fee | $9,806 |
|---|---|
| Food and Beverage | $512 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Consulting Fee | $4,560 |
| Eisai Inc. Nov 5, 2025 | Consulting Fee Leqembi · Neurology | $3,180 |
| UCB SA Jan 10, 2025 | Consulting Fee | $1,375 |
| E.r. Squibb & Sons, L.l.c. Aug 13, 2025 | Consulting Fee | $691 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $3,237,480 in research payments for these studies, mostly to the institutions running them.
- A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) an…
Eisai Inc. - A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
UCB SA · Completed · NCT04867616 - Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205
Biogen, Inc. - A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc. - A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Biogen, Inc. - A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.